AstraZeneca plc (NASDAQ:AZN) has been granted approval by the U.S. Food and Drug Administration for a new self-injection ...

AstraZeneca’s SAPHNELO ® (anifrolumab-fnia) has been approved in the US for self-administration as a once-weekly autoinjector, the SAPHNELO Pen , for the treatment of adult patients with systemic ...

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceuticals giant, faces no material risk from its Japanese partner ...

AstraZeneca announced in May 2026 that its drug Ultomiris significantly reduced urine protein levels in patients with IgA ...

We just covered the 14 Best Low Risk High Growth Stocks to Buy Right Now and AstraZeneca PLC (NYSE:AZN) ranks 5th on this ...

AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has served up a third phase 3 win this year, offering ...

AstraZeneca PLC (NYSE:AZN) is one of the best stem cell therapy stocks to buy. AstraZeneca PLC (NYSE:AZN) announced on April ...

April 21 () - AstraZeneca said on Tuesday its rare blood disorder drug Ultomiris has met ‌the main goal of a late-stage trial ...

Speaking to German newspaper Handelsblatt, CEO Pascal Soriot said proposed cost-cutting measures in the country’s healthcare ...

FRANKFURT, April 21 (Reuters) - AstraZeneca's CEO told daily Handelsblatt on Tuesday that Germany risks missing out on new ...

A federal appellate court has handed down the first appellate-level decision addressing the merits of drug manufacturers’ challenges to the Inflation Reduction Act of 2022's (IRA) Medicare Drug ...

Step aside football, basketball and hockey, AstraZeneca is bringing its sports marketing efforts to the fastest-growing sport in America — pickleball. The pharma giant recently announced a partnership ...